211364-69-1

Basic information

• Product Name: Mono-POC Tenofovir
• Synonyms: Mono-POC Tenofovir;Mono-POC Tenofovir (Mixture of DiastereoMers);((((R)-1-(6-aMino-9H-purin-9-yl)propan-2-yloxy)Methyl)(hydroxy)phosphoryloxy)Methyl isopropyl carbonate;Mono-POC PMPA;tenofovirMonoester;Tenofovir Disoproxil Related CoMpound E;(8R)-9-(6-Amino-9H-purin-9-yl)-5-hydroxy-8-methyl-2,4,7-trioxa-5-phosphanonanoic acid 1-methylethyl ester 5-oxide;Tenofovir monoisoproxil
• CAS NO: 211364-69-1
• Molecular Formula: C14H22N5O7P
• Molecular Weight: 403.327541
• Product Categories: Amines;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Phosphorylating and Phosphitylating Agents
• Mol File: 211364-69-1.mol
• Article Data: 8

Chemical Properties

• Melting Point: 303-305°C (dec.)
• Boiling Point: 599.297°C at 760 mmHg
• Flash Point: 316.244°C
• Appearance: /
• Density: 1.562g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• Solubility: Dichloromethane (Slightly), Methanol (Slightly, Heated), Water (Slightly)
• PKA: 1.88±0.10(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: Mono-POC Tenofovir(CAS DataBase Reference)
• NIST Chemistry Reference: Mono-POC Tenofovir(211364-69-1)
• EPA Substance Registry System: Mono-POC Tenofovir(211364-69-1)

Safety Data

• Hazardous Substances Data: 211364-69-1(Hazardous Substances Data)

Usage

Description

Mono-POC Tenofovir, also known as Tenofovir Disoproxil (T018505(P)), is an acyclic phosphonate nucleotide analogue and a reverse transcriptase inhibitor. It is a white solid substance with potent antiviral properties, making it a significant pharmaceutical compound.

Uses

Used in Pharmaceutical Industry:
Mono-POC Tenofovir is used as an anti-HIV agent for its ability to inhibit the replication of the human immunodeficiency virus (HIV). It plays a crucial role in the treatment and management of HIV/AIDS by suppressing the viral load and helping to prevent the progression of the disease.
Used as an Antiviral:
In the field of antiviral research and treatment, Mono-POC Tenofovir is utilized as a potent antiviral agent. Its reverse transcriptase inhibitory properties make it effective against various viral infections, including HIV. It works by blocking the activity of reverse transcriptase, an enzyme essential for the replication of certain viruses, thus limiting their ability to multiply and spread within the host.
Used in Research and Development:
Mono-POC Tenofovir is also used in the research and development of new antiviral drugs and therapies. Its unique chemical properties and potent antiviral activity make it a valuable compound for studying the mechanisms of viral replication and the development of novel treatments for viral infections.

InChI:InChI=1/C14H22N5O7P/c1-9(2)26-14(20)23-7-25-27(21,22)8-24-10(3)4-19-6-18-11-12(15)16-5-17-13(11)19/h5-6,9-10H,4,7-8H2,1-3H3,(H,21,22)(H2,15,16,17)

Upstream product

• 35180-01-9 chloromethyl isopropyl carbonate 
• 147127-20-6 tenofovir 
• 180587-75-1 (R)-diethyl (((1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate 
• 14047-28-0 (R)-9-(2-hydroxypropyl)adenine 
• 66224-66-6 adenine 
• 201341-05-1 tenofovir disoproxil 
• 201341-05-1 bis-isopropyloxycarbonylmethyl 9-((R)-2-(phosphonomethoxy)propyl)adenine 

Downstream Products

• 1246812-40-7 propan-2-yl {[(propan-2-yloxy)carbonyl]oxy}methyl {[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methanephosphonate 

Relevant articles and documents

Degradation kinetics of oxycarbonyloxymethyl prodrugs of phosphonates in solution

-

Tenofovir phenyl propionate phosphoramidate compound as well as pharmaceutical composition and application thereof

The invention discloses a tenofovir phenyl propionate phosphoramidate compound as well as a pharmaceutical composition and an application of the tenofovir phenyl propionate phosphoramidate compound. The tests prove that the compound has the activity of inhibiting HBV virus replication, and has the advantages of higher activity, lower toxicity and the like than the existing drug tenofovir disoproxil fumarate (TDF) for treating AIDS. The experiments also prove that the compound also has the activity of inhibiting HIV-1 virus replication, and can be used for developing medicines for treating AIDSor medicines for treating hepatitis B.

Tenofovir disoproxil fumarate analog preparation method

The present invention discloses a tenofovir disoproxil fumarate analog preparation method, which comprises: carrying out a substitution reaction on adenine as a raw material and (R)-propylene carbonate in the presence of an alkali, carrying out a substitution reaction with (diethoxyphosphoryl)methyl-4-methylbenzenesulfonate, hydrolyzing with a concentrated hydrochloric acid solution, crystallizingto obtain anhydrous tenofovir, carrying out a reaction on the anhydrous tenofovir and chloromethyl isopropyl carbonate to obtain tenofovir monoester, and carrying out a reaction with 2-bromopropane to obtain the target compound. According to the present invention, the selected starting raw materials are inexpensive and easy to obtain, the process is simple, and the material utilization rate and total yield are improved; and the intermediate of the method is purified by re-crystallization, such that the yield is high, and the purity is high.